Company intelligence / Profile preview

Marathon Bio

Northbrook, Illinois, United States

Ownership: Private
Employees: ~100
Development stage: Other

Overview

The company’s lead product was deflazacort (Emflaza), approved by the FDA to treat Duchenne muscular dystrophy. The drug was acquired by PTC Therapeutics in 2017 after controversy over pricing. Other pipeline assets were discontinued.

Therapeutic areas: RheumatologyRare DiseasesNeurologyOncology
Modalities: Small molecule
Industry: Biotech

Partnerships

Asset sale to PTC Therapeutics

Beyond the preview

Go deeper on Marathon Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Marathon Bio.

Explore the full profile